These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1442 related items for PubMed ID: 29808796

  • 1. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 2. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
    Ozkan T, Hekmatshoar Y, Pamuk H, Ozcan M, Yaman G, Yagiz GC, Akdemir C, Sunguroglu A.
    Mol Biol Rep; 2021 Feb 15; 48(2):1625-1631. PubMed ID: 33515349
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T, Cao J, Zou F, Li X, Wang A, Wang W, Liang H, Liu Q, Hu C, Chen C, Hu Z, Wang W, Li L, Ge J, Shen Y, Ren T, Liu J, Xia R, Liu Q.
    Eur J Pharmacol; 2021 Apr 15; 897():173944. PubMed ID: 33581133
    [Abstract] [Full Text] [Related]

  • 4. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
    Lee CR, Kang JA, Kim HE, Choi Y, Yang T, Park SG.
    FEBS Lett; 2016 Feb 15; 590(3):358-68. PubMed ID: 26831735
    [Abstract] [Full Text] [Related]

  • 5. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Feb 15; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 6. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L, Liu H, Huang J, Xie W, Wei J, Ye X, Qian W.
    Oncotarget; 2017 Jan 31; 8(5):7777-7790. PubMed ID: 27999193
    [Abstract] [Full Text] [Related]

  • 7. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS.
    Cancer Lett; 2016 Dec 28; 383(2):220-229. PubMed ID: 27720778
    [Abstract] [Full Text] [Related]

  • 8. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA.
    Tumour Biol; 2016 Sep 28; 37(9):12643-12654. PubMed ID: 27444277
    [Abstract] [Full Text] [Related]

  • 9. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.
    PLoS One; 2017 Sep 28; 12(7):e0179558. PubMed ID: 28719608
    [Abstract] [Full Text] [Related]

  • 10. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW, Lee YL, Liou JP, Liu YH, Liu CW, Chen TY, Huang HM.
    Apoptosis; 2016 Sep 28; 21(9):1008-18. PubMed ID: 27344662
    [Abstract] [Full Text] [Related]

  • 11. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA, Jusoh SA, Yong AC, Asan JM, Hassan R, Johan MF.
    Asian Pac J Cancer Prev; 2014 Sep 28; 15(11):4555-61. PubMed ID: 24969884
    [Abstract] [Full Text] [Related]

  • 12. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK, Ceylan C, Elmas E, Baran Y.
    Tumour Biol; 2016 Feb 28; 37(2):2365-78. PubMed ID: 26373734
    [Abstract] [Full Text] [Related]

  • 13. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.
    Leuk Res; 2014 Apr 28; 38(4):454-9. PubMed ID: 24456693
    [Abstract] [Full Text] [Related]

  • 14. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z, Jung KH, Yan HH, Kim SJ, Son MK, Rumman M, Lee H, Kim KW, Yoo HD, Hong SS.
    Int J Oncol; 2015 Jul 28; 47(1):253-61. PubMed ID: 25963192
    [Abstract] [Full Text] [Related]

  • 15. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Carter BZ, Wang X, Shi X, Liu J.
    J Hematol Oncol; 2016 Nov 25; 9(1):129. PubMed ID: 27884201
    [Abstract] [Full Text] [Related]

  • 16. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY, Liou JP, Lee YL, Lin JY, Huang HM.
    Invest New Drugs; 2017 Aug 25; 35(4):427-435. PubMed ID: 28349229
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2.
    Deng Y, Li X, Feng J, Zhang X.
    Biosci Rep; 2018 Jun 29; 38(3):. PubMed ID: 29559564
    [Abstract] [Full Text] [Related]

  • 18. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P, Johnson K, O'Dwyer ME, Druker BJ.
    Exp Hematol; 2002 Jul 29; 30(7):729-37. PubMed ID: 12135670
    [Abstract] [Full Text] [Related]

  • 19. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Wang X, Shi X, Liu J.
    Cell Death Dis; 2017 Jul 06; 8(7):e2913. PubMed ID: 28682311
    [Abstract] [Full Text] [Related]

  • 20. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, Clark RE, Mitra S, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL, Helgason GV.
    J Natl Cancer Inst; 2018 May 01; 110(5):467-478. PubMed ID: 29165716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.